18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Global industry news
With U.S. elections nearing, European pharma giants brace for potential pricing action: analysts
Sun Pharma the latest to recall metformin after carcinogen tests come up positive
ICER rubber-stamps Vertex's $311K CF drug Trikafta but blasts 'monopoly' pricing
+7 495 442 37 85
+7 985 908 58 18
Registration of Medical Drugs in Russia
Registration of Pharmaceuticals in Russia
Registration of Pharmaceutical Dossier Variations in Russia
Registration of Pharmaceuticals in CIS
Clinical Studies in Russia
Clinical Studies for Registration of Pharmaceuticals in Russia
International Phase III Clinical Studies
Phase I, Phase II (IIa, IIb) Clinical Studies
Preclinical Studies in Russia
Preclinical Studies for Registration of Pharmaceuticals in Russia
Preclinical Studies for Registration of Biopharmaceuticals in Russia
In Vitro Preclinical Studies in Russia
Regulatory Consulting in Russia and EEU
Certification of Medical Drugs and Medical Devices in Russia
Registration of Medical Devices in Russia
Russian GMP inspection of pharmaceutical manufacturers
Regulatory Events Russia
Russian Regulatory News
You are here:
Pharegis LLC / ООО "Фареджис"
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
TAX ID (TIN): 7718278100
+7 495 442 37 85 9am-6pm GMT+3
+ 7 495 442 37 85
+ 7 985 908 58 18
Send an Email
Send a copy to yourself
SHARE THIS BY:
Create an account
Forgot your username?
Forgot your password?
Drugs.com - New Drug Approvals
FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of Asthma
FDA Approves Qdolo (tramadol hydrochloride) Oral Solution for the Management of Severe Pain
FDA Approves Detectnet (copper Cu 64 dotatate injection) Positron Emission Tomography (PET) Agent
FDA Approves Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
FDA Approves Additional Doses of Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes
News and press releases
Guideline on registry-based studies - launch of public consultation, , 24/09/2020
How incidents with medicines are managed in the EU – a ten-year analysis, , 23/09/2020
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020, CHMP, 18/09/2020
New oral treatment for moderate to severe atopic dermatitis, CHMP, 18/09/2020
Drugs.com - Clinical Trials
Anti-Influenza Drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 Patients
TOKYO — September 23,...
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J.,...
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
ROCKVILLE, MD, Sept. 22,...
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer
Tokyo, Basking Ridge, N.J....
PharmaTimes: PharmaTimes Website RSS
Oncimmune partners with Genentech to profile samples from rheumatology trials
Verona Pharma launches late-stage COPD trial programme
FDA and EMA accept regulatory submissions for UCB’s bimekizumab
NHS COVID-19 app launches in England and Wales
Digital tech has health benefits for dementia patients, project finds
Terms of Service
Sample Non-Disclosure Agreement